I think it's important to focus on what will make a difference.
What do you think is more likely:
- that a change in strategy (maybe doing the studies initially asked for and getting more evidence of efficacy) is more likely to lead to a successful submission
OR
- that the FDA will have some change in philosophy, or leadership, or change their policies, in time for MSB to get their approval before their cash runs out?
I honestly don't think either is likely to happen. But I am dumbfounded by where you are directing your attention, and honestly can't imagine the strategy involved.
Ann: Mesoblast Type A Meeting with FDA, page-456
-
- There are more pages in this discussion • 119 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
0.025(2.70%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| 94.0¢ | 96.8¢ | 93.5¢ | $4.207M | 4.417M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 42268 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.0¢ | 48002 | 3 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |